Bayesian inference for optimal dynamic treatment regimes in practice.

Abstract

In this work, we examine recently developed methods for Bayesian inference of optimal dynamic treatment regimes (DTRs). DTRs are a set of treatment decision rules aimed at tailoring patient care to patient-specific characteristics, thereby falling within the realm of precision medicine. In this field, researchers seek to tailor therapy with the intention of improving health outcomes; therefore, they are most interested in identifying optimal DTRs. Recent work has developed Bayesian methods for identifying optimal DTRs in a family indexed by ψ via Bayesian dynamic marginal structural models (MSMs) (Rodriguez Duque D, Stephens DA, Moodie EEM, Klein MB. Semiparametric Bayesian inference for dynamic treatment regimes via dynamic regime marginal structural models. Biostatistics; 2022. (In Press)); we review the proposed estimation procedure and illustrate its use via the new BayesDTR R package. Although methods in Rodriguez Duque D, Stephens DA, Moodie EEM, Klein MB. (Semiparametric Bayesian inference for dynamic treatment regimes via dynamic regime marginal structural models. Biostatistics; 2022. (In Press)) can estimate optimal DTRs well, they may lead to biased estimators when the model for the expected outcome if everyone in a population were to follow a given treatment strategy, known as a value function, is misspecified or when a grid search for the optimum is employed. We describe recent work that uses a Gaussian process prior on the value function as a means to robustly identify optimal DTRs (Rodriguez Duque D, Stephens DA, Moodie EEM. Estimation of optimal dynamic treatment regimes using Gaussian processes; 2022. Available from: https://doi.org/10.48550/arXiv.2105.12259). We demonstrate how a approach may be implemented with the BayesDTR package and contrast it with other value-search approaches to identifying optimal DTRs. We use data from an HIV therapeutic trial in order to illustrate a standard analysis with these methods, using both the original observed trial data and an additional simulated component to showcase a longitudinal (two-stage DTR) analysis.